Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer

Authors: Zhan-Dong Zhang, Ye Kong, Wei Yang, Bin Zhang, Yong-Lei Zhang, Er-Min Ma, Hong-Xing Liu, Xiao-Bin Chen, Ya-Wei Hua

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

The prognosis of patients with advanced gastric cancer is poor. The goal of this study was to evaluate the efficacy and safety of combination therapy of cetuximab and S-1 combined with oxaliplatin (SOX) in Chinese patients with advanced gastric cancer.

Methods

For patients in the experimental group (cetuximab in combination with SOX (Ce-SOX), 30 patients), once-weekly cetuximab (400 mg/m2 at the first infusion then 250 mg/m2 every week) was administered. For patients in both the control (SOX alone, 26 patients) and experimental groups, oxaliplatin (100 mg/m2) was administered intravenously on day 1, while S-1 (80 mg/m2/day) was given orally twice daily for 14 days. The endpoints of this study included progression-free survival, response rate, and disease-control rate.

Results

There was no statistically significant difference in response rate between the Ce-SOX and SOX groups (54.8% versus 44%, P = 0.225). The difference in disease-control rate was also statistically insignificant between the two groups (87.1% versus 76%, P = 0.162). Median progression-free survival in the Ce-SOX group was significantly higher than that in the SOX group (12.8 versus 10.1 months, P = 0.007). The median overall survival of the Ce-SOX group and SOX group was 14.0 and 12.2 months, respectively (P = 0.043). The one-year survival rate for the Ce-SOX group was 57% compared to 40% in the SOX group. There was no statistical difference in the grade 3 or 4 adverse effects between the two groups.

Conclusions

These findings suggest that the cetuximab combined with SOX regimen is feasible and shows promising efficacy with tolerable adverse effects in Chinese patients with advanced gastric cancer.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Wang X, Wang ML, Zhou LY, Lu XY, Yang JF, Yu HG: Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer. Clin Transl Oncol. 2013, 15: 836-842.CrossRefPubMed
4.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90.CrossRefPubMed
5.
Lee HH, Hur H, Kim SH, Park AR, Kim W, Jeon HM: Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat. 2010, 42: 18-23.PubMedCentralCrossRefPubMed
6.
Gao SG, Jia RN, Feng XS, Xie XH, Shan TY, Pan LX, Song NS, Wang YF, Ding KL, Wang LD: Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma. World J Gastroenterol. 2011, 17: 5221-5226.PubMedCentralCrossRefPubMed
7.
Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the flags trial. J Clin Oncol. 2010, 28: 1547-1553.CrossRefPubMed
8.
Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008, 9: 215-221.CrossRefPubMed
9.
Rosati G, Ferrara D, Manzione L: New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol. 2009, 15: 2689-2692.PubMedCentralCrossRefPubMed
10.
Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, Komatsu Y, Tsuburaya A: Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2010, 21: 1001-1005.CrossRefPubMed
11.
Park I, Lee JL, Ryu MH, Chang HM, Kim TW, Sym SJ, Lee SS, Jang G, Yoo C, Bae KS, Kang YK: Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 2010, 65: 473-480.CrossRefPubMed
12.
Oh SY, Kwon HC, Jeong SH, Joo YT, Lee YJ, Cho S, Kang MH, Go SI, Lee GW, Kim H, Kang JH: A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Invest New Drugs. 2012, 30: 350-356.CrossRefPubMed
13.
Liu B, Ying J, Luo C, Xu Q, Zhu L, Zhong H: S-1 Combined with oxaliplatin as first line chemotherapy for Chinese advanced gastric cancer patients. Hepatogastroenterology. 2012, 59: 649-653.PubMed
14.
Baselga J: The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer. 2001, 37: 16-22.CrossRef
15.
Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ: Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007, 357: 2040-2048.CrossRefPubMed
16.
Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007, 25: 2171-2177.CrossRefPubMed
17.
18.
Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S: Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol. 2011, 22: 1358-1366.CrossRefPubMed
19.
Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Höfler H, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, Lordick F: Cetuximab plusoxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer. 2010, 102: 500-505.PubMedCentralCrossRefPubMed
20.
Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5- fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the arbeitsgemeinschaft internistische onkologie. Ann Oncol. 2009, 20: 1667-1673.CrossRefPubMed
21.
Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA: Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastrooesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009, 101: 1261-1268.PubMedCentralCrossRefPubMed
22.
Woll E, Kuhr T, Eisterer W, Gattringer K, Greil R, Zabernigg A, Hilbe W, Thaler J: Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. a first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT). Anticancer Res. 2008, 28: 2901-2905.PubMed
23.
Shi M, Ji J, Wu J, Ma T, Liu Y, Zhou CF, Su Y, Ye ZB, Zhang J, Zhu ZG: Cetuximab combined with FOLFOX4 as the first-line treatment for advanced gastric cancer: report of 25 cases from a single institution. Hepatogastroenterology. 2012, 59: 1054-1058.PubMed
24.
Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles A, Busch R, Hermannstädter C, Nährig J, Becker KF, Becker I, Höfler H, Fend F, Luber B: Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol. 2004, 17: 579-587.CrossRefPubMed
25.
Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006, 24: 4922-4927.CrossRefPubMed
26.
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26: 1626-1634.CrossRefPubMed
27.
Kim IJ, Park JH, Kang HC, Shin Y, Park HW, Park HR, Ku JL, Lim SB, Park JG: Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet. 2003, 114: 118-120.CrossRefPubMed
28.
Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Nam SW, Kim SH, Lee JY, Yoo NJ: BRAF and KRAS mutations in stomach cancer. Oncogene. 2003, 22: 6942-6945.CrossRefPubMed
29.
Zhao W, Chan TL, Chu KM, Chan AS, Stratton MR, Yuen ST, Leung SY: Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability. Int J Cancer. 2004, 108: 167-169.CrossRefPubMed
30.
Rivera F, Vega-Villegas ME, Lopez-Brea MF: Chemotherapy of advanced gastric cancer. Cancer Treatt Rev. 2007, 33: 315-324.CrossRef
31.
Xu R, Ma N, Wang F, Ma L, Chen R, Chen R, Kebinu M, Ma L, Han Z, Ayixiamu , Mayier M, Su P, Naman Y, Jieensi H, Yang H, Adili A, Aili S, Liu J, Mayier M, Su P, Naman Y, Jieensi H, Yang H, Adili A, Aili S, Liu J: Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with endostar and S-1 combined with oxaliplatin in advanced gastric cancer. Onco Targets Ther. 2013, 6: 925-929.PubMedCentralPubMed
32.
Amedei A, Benagiano M, della Bella C, Niccolai E, Benagiano M, Bella C, Niccolai E, D’Elios MM: Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol. 2011, 2011: 437348-PubMedCentralCrossRefPubMed
33.
Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M: Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013, 14: 490-499.CrossRefPubMed
34.
Li T, Chen L: Efficacy and safety of SOX regimen as neoadjuvantn chemotherapy for advanced gastric cancer. Zhonghua Wei Chang Wai Ke Z a Zhi. 2011, 14: 104-106.
35.
Tao L, Zhe L, Jian Z: Clinical evaluation of the combination of S-1 and oxaliplatin in the treatment of patients with advanced gastric cancer. Med Innov of China. 2013, 10: 25-26.
36.
Kang ZX, Ceng HX, Guo SJ: Clinical curative effect observation of oxaliplatin combined S1 in treatment of 52, cases with advanced gastric cancer. China Foreign Med Treat. 2013, 32: 22-24.
37.
Fan WF, Wang J, Meng LJ, Liu FY, Pu XL, Yang M: Clinical study of S-1 plus oxanplatin versus S-l plus cisplatin as the first-line treatment for elderly patients with advanced gastric cancer. Chinese Clin Oncol. 2013, 18: 50-53.
Metadata
Title
Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer
Authors
Zhan-Dong Zhang
Ye Kong
Wei Yang
Bin Zhang
Yong-Lei Zhang
Er-Min Ma
Hong-Xing Liu
Xiao-Bin Chen
Ya-Wei Hua
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-115

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue

Case report

Laparoscopic surgery for double gastrointestinal stromal tumor of the stomach: a report of two cases

Research

Does young age influence the prognosis of colorectal cancer: a population-based analysis

Case report

Malawer limb salvage surgery for the treatment of scapular chondrosarcoma

Case report

The challenge of extraabdominal desmoid tumour management in patients with Gardner’s syndrome: radiofrequency ablation, a promising option

Case report

Primary diffuse large B-cell lymphoma of the chest wall: a case report

Case report

Suprarenal solitary fibrous tumor associated with a NF1 gene mutation mimicking a kidney neoplasm: implications for surgical management